- Contributing to improve quality of life for OUD patients and reduce overdose morbidity through improved access to treatment and treatment support.
- Based on the AmorphOX® platform develop new medications reducing the need for cold storage and thereby improve access to medication in areas where controlled storage facilities are sparse.
Focus area
Access to healthcare
The focus area's vision: Increase access to healthcare among patients with OUD and develop innovative medications meeting large unmet needs
The opioid epidemic continues to be one of the most pressing health challenges in the US, exacerbated by the ongoing impacts of stigma and treatment barriers. In response, Orexo remains dedicated to addressing this crisis, working tirelessly to improve access to essential care and lifesaving medications. Indeed, the work done throughout 2024 is enabling more patients to receive the care they need for better health outcomes, and to save lives.
UN Sustainable Development Goals
Accessibility
At least one drug based on the AmorphOX platform that meets the need for improved shelf life and does not require cold storage has reached global markets through partnerships.
Continuous work during the year, e.g., 2nd clinical study successfully conducted with OX640, a nasal epinephrine product.
Affordability
More financial vulnerable individuals have access to Orexo’s products.
- 100% of Orexo’s pharmaceutical products are reimbursed and its market access position in the public commercial payer segment is growing.1
- 100% of Orexo’s pharmaceutical products have patient assistant programs in place.
1. Annual average increase from base year 2023
- 50% of patients in the public segment can have Zubsolv® reimbursed, a flat development versus 2023.
- 100% of the pharma products (Zubsolv) are reimbursed and have patient assistant programs in place.
Orexo's Zubsolv has the potential to help
~5.7* million
people in the US towards an OUD free life
*Number of people suffering from opioid dependence in the US. Source: SAMHSA Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health.
